Spots Global Cancer Trial Database for Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Official Title: Pilot Study of Lenalidomide and Dexamethasone in Combination With MEDI-551 in Previously Untreated Multiple Myeloma.
Study ID: NCT01861340
Conditions
Interventions
Study Description
Brief Summary: This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.
Detailed Description: To explore the effect of Lenalidomide, dexamethasone and Medi-551 on multiple myeloma cancer stem cells (CSCs). Myeloma CSCs will be assessed by a clonogenic assay from the bone marrow and flow cytometry from peripheral blood.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Contact Details
Name: Carol Ann Huff, MD
Affiliation: The Johns Hopkins University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
